The global Gastrointestinal Therapeutics market size is expected to be worth around US$ 75.1 billion by 2030, according to a new report by Vision Research Reports.
The global Gastrointestinal Therapeutics market size was valued at US$ 61.9 billion in 2020 and is anticipated to grow at a CAGR of 16.6% during forecast period 2021 to 2030.
Growing geriatric population prone to gastrointestinal indications is one of the key factors anticipated to contribute to market growth. According to a report by WHO, colon cancer caused nearly 694,000 deaths in 2014.
Growing geriatric population, especially in emerging economies, is expected to drive market growth over the coming years. Furthermore, initiatives undertaken by the Centers for Disease Control and Prevention (CDC) to promote cancer screening nationwide is expected to boost market growth over the forecast period. The Division of Cancer Prevention and Control (DCPC) supports National Colorectal Cancer Action Campaign (NCCCP) and provides funds to aid research studies and implement strategies to control colorectal cancer. This increase in initiatives for screening is expected to fuel sales of therapeutics and present lucrative growth opportunities to the market.
Branded gastrointestinal drugs held the dominant share by product in 2016. However, it is expected to witness a decline in CAGR throughout the forecast period. This decline can be attributed to increasing penetration of generics in the market, resulting in sales erosion of leading brands and fewer novel product launches. Some of the high revenue generating drugs in gastrointestinal therapeutics that are slated to expire in the near future are Emend, Sandostatin, Humira, Linzess, and Aloxi. This is anticipated to restrict growth of branded drugs.
Moreover, patients suffering from acute gastrointestinal bacterial infections, previously treated with antibiotics, are unwilling to adopt new treatment regimens. In addition, increase in multidrug-resistant strains poses a challenge during treatment, which is expected to hinder the growth of branded drugs.
The generic segment is expected to grow at an exponential rate throughout the forecast period owing to consistent expiries of patents, cost-effectiveness of generics, and initiatives by government organizations for promoting usage of generics in emerging economies. In addition, major pharmaceutical companies are consistently striving to launch generic versions of their branded counterparts to recover losses caused by patent expiration.
Branded drug manufacturers and generic producing firms are collaborating for producing generic drugs after patent expiry, which is expected to boost the growth of generics. In addition, major firms are increasingly focusing on developing generics owing to increase in off-patented drugs in the market. However, marketing exclusivity given by the FDA to patent holders for different indications is anticipated to hinder market growth to a slight extent.
intravenous accounted for the dominant share on the basis of route of administration. The substantial share is anticipated to be a result of benefits associated with IV products. It can also be attributed to high price of IV products as compared to oral products. Such products include Humira, Sandostatin, Aldurazyme, Elelyso, Naglazyme, Myozyme, Vimizim, Donnatal, Pamine, Aloxi, Pepcid AC, Remicade, Tysabri, Entyvio, and Remsima.
In terms of volume, oral products accounted for the largest share; however, in terms of revenue, the intravenous segment accounts for the dominant share. Benefits such as ease of administration and long-term cost efficiency are major factors fueling the adoption of these products over the years.
Oral products accounted for the second-largest share in the market for gastrointestinal therapeutics in 2016. This is a consequence of high efficacy of oral gastrointestinal agents due to direct contact with affected areas. However, other routes such as intravenous and transdermal have greater bioavailability in comparison to oral products, which may result in considerable decrease in demand. In addition, oral products are not found to be convenient for patients in younger age groups. Moreover, there is a greater probability of contraindication and toxic drug interactions in case of patients undergoing gastrointestinal cancer treatment.
The others segment accounted for the largest share by application in 2016. This segment includes opioid-induced constipation, chronic idiopathic constipation, diarrhea, recurrent gastrointestinal infections, nausea, gastrointestinal stromal tumor, pancreatic insufficiency, and irritable bowel syndrome. The substantial share can be attributed to a wide range of applications for which gastrointestinal drugs have been used consistently over the previous years. Frequent number of drug launches is also responsible for increased scope for growth.
Ulcerative colitis accounted for the second-largest share in the gastrointestinal therapeutics market in 2016. Growth of this segment can be attributed to easy availability of drugs to treat this condition. The segment is also anticipated to grow at a considerable rate owing to high clinical urgency to curb growing prevalence of ulcerative colitis. This high prevalence is due to poor prognosis and consumption of unhealthy food, which may result in high probability of disease recurrence.
The Crohn’s disease segment is anticipated to witness a lucrative growth rate throughout the forecast period. Rising prevalence of lifestyle-induced conditions such as excessive drinking and high incidence of chronic diseases such as cancer and diabetes, are major growth-rendering drivers. According to the CDC, approximately 1.0-1.3 million people are suffering from Inflammatory Bowel Disease (IBD). In U.S., prevalence of Crohn’s disease is 201 per 100,000 adults.
retail pharmacy accounted for the dominant share in terms of distribution channel owing to high affordability and accessibility to retail stores. As number of prescription medicines being reimbursed is increasing, it is encouraging patients to purchase medicines from retail pharmacies. Retail pharmacists also recommend drug substitutes that prevent adverse drug interactions.
These factors are likely to boost customer inclination toward retail stores. In case retail pharmacists have any concerns regarding prescribed medicines, they recommend alternatives for the same, thus ensuring higher safety. Advent of pharmacy chains such as CVS Health is a major contributor to the share of the retail segment. Adoption of digitalized systems in retail pharmacies to reduce risk of errors in prescriptions is also anticipated to fuel growth over the coming years.
Online pharmacies are expected to exhibit lucrative growth during the forecast period. This growth is anticipated to be a consequence of associated benefits such as high convenience for bed-ridden patients who find it difficult to purchase medicines from hospitals or retail stores. In addition, growing incidence of chronic diseases has resulted in a wide gap in the supply of and demand for major drugs. The aforementioned factors are expected to present remunerative growth prospects for online pharmacies during the forecast period.
With the advent of online pharmacies, tracking and order procurement have become convenient. Supply Chain Management (SCM) in online pharmacies enables integration of various market intermediaries of the delivery channel, which reduces overall cost, thereby further driving demand for this segment.
The North America market accounted for the largest share in 2016 and is expected to maintain its position during the forecast period. This substantial share can be attributed to unprecedented change in lifestyle, resulting in greater incidence of gastrointestinal diseases.
Moreover, presence of government initiatives aimed at preventing as well as treating gastrointestinal diseases is expected to drive the market. For instance, the Integrated Global Action Plan for Diarrhoea by UNICEF and WHO aims at minimizing preventable childhood deaths as a result of diarrhea by providing interventions and services to raise awareness and provide access to treatment and preventive measures.
Asia Pacific is anticipated to exhibit exponential growth throughout the forecast period. This is likely to be fueled by consistent efforts undertaken by key players, which include R&D investments as well as commercialization of branded drugs at a relatively lower price. In addition, urgent need to curb high incidence rate of gastrointestinal disorders and technological upgradation of healthcare infrastructure are predicted to present the regional market with high potential growth opportunities over the forecast period.
Allergan plc.;AstraZeneca plc.; GlaxoSmithKline plc; Johnson & Johnson; Takeda Pharmaceuticals; Salix Pharmaceuticals, Inc.; Pfizer, Inc.; AbbVie, Inc.; Abbott Laboratories; Bayer AG.
Type Outlook (Revenue, USD Million, 2014 - 2025)
Enzyme Replacement Therapies
Route of Administration Outlook (Revenue, USD Million, 2014 - 2025)
Application Outlook (Revenue, USD Million, 2014 - 2025)
Distribution Channel Outlook
Middle East & Africa
The Gastrointestinal Therapeutics market research report covers definition, classification, product classification, product application, development trend, product technology, competitive landscape, industrial chain structure, industry overview, national policy and planning analysis of the industry, the latest dynamic analysis, etc., and also includes major. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level.
The report provides size (in terms of volume and value) of Gastrointestinal Therapeutics market for the base year 2020 and the forecast between 2021 and 2030. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.
This report focuses on the global Gastrointestinal Therapeutics market status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Gastrointestinal Therapeutics market development in United States, Europe and China.
It is pertinent to consider that in a volatile global economy, we haven’t just conducted Gastrointestinal Therapeutics market forecasts in terms of CAGR, but also studied the market based on key parameters, including Year-on-Year (Y-o-Y) growth, to comprehend the certainty of the market and to find and present the lucrative opportunities in market.
In terms of production side, this report researches the Gastrointestinal Therapeutics capacity, production, value, ex-factory price, growth rate, market share for major manufacturers, regions (or countries) and type.
In terms of consumption side, this report focuses on the consumption of Gastrointestinal Therapeutics by regions (countries) and application.
Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of production analysis, the authors of the report have provided reliable estimations and calculations for global revenue and volume by Type segment of the global Gastrointestinal Therapeutics market. These figures have been provided in terms of both revenue and volume for the period 2017 to 2030. Additionally, the report provides accurate figures for production by region in terms of revenue as well as volume for the same period. The report also includes production capacity statistics for the same period.
With regard to production bases and technologies, the research in this report covers the production time, base distribution, technical parameters, research and development trends, technology sources, and sources of raw materials of major Gastrointestinal Therapeutics market companies.
Regarding the analysis of the industry chain, the research of this report covers the raw materials and equipment of Gastrointestinal Therapeutics market upstream, downstream customers, marketing channels, industry development trends and investment strategy recommendations. The more specific analysis also includes the main application areas of market and consumption, major regions and Consumption, major Chinese producers, distributors, raw material suppliers, equipment providers and their contact information, industry chain relationship analysis.
The research in this report also includes product parameters, production process, cost structure, and data information classified by region, technology and application. Finally, the paper model new project SWOT analysis and investment feasibility study of the case model.
Overall, this is an in-depth research report specifically for the Gastrointestinal Therapeutics industry. The research center uses an objective and fair way to conduct an in-depth analysis of the development trend of the industry, providing support and evidence for customer competition analysis, development planning, and investment decision-making. In the course of operation, the project has received support and assistance from technicians and marketing personnel in various links of the industry chain.
The Gastrointestinal Therapeutics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to Gastrointestinal Therapeutics market.
Prominent players in the market are predicted to face tough competition from the new entrants. However, some of the key players are targeting to acquire the startup companies in order to maintain their dominance in the global market. For a detailed analysis of key companies, their strengths, weaknesses, threats, and opportunities are measured in the report by using industry-standard tools such as the SWOT analysis. Regional coverage of key companies is covered in the report to measure their dominance. Key manufacturers of Gastrointestinal Therapeutics market are focusing on introducing new products to meet the needs of the patrons. The feasibility of new products is also measured by using industry-standard tools.
Key companies are increasing their investments in research and development activities for the discovery of new products. There has also been a rise in the government funding for the introduction of new Gastrointestinal Therapeutics market. These factors have benefited the growth of the global market for Gastrointestinal Therapeutics. Going forward, key companies are predicted to benefit from the new product launches and the adoption of technological advancements. Technical advancements have benefited many industries and the global industry is not an exception.
New product launches and the expansion of already existing business are predicted to benefit the key players in maintaining their dominance in the global market for Gastrointestinal Therapeutics. The global market is segmented on the basis of region, application, en-users and product type. Based on region, the market is divided into North America, Europe, Asia-Pacific, Latin America and Middle East and Africa (MEA).
In this study, the years considered to estimate the market size of Gastrointestinal Therapeutics are as follows:
Reasons to Purchase this Report:
- Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
- Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
- Market value USD Million and volume Units Million data for each segment and sub-segment
- Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
- Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.
This research study involved the extensive usage of both primary and secondary data sources. The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. The following illustrative figure shows the market research methodology applied in this report.
Market Size Estimation
Top-down and bottom-up approaches are used to estimate and validate the global market size for company, regional division, product type and application (end users).
The market estimations in this report are based on the selling price (excluding any discounts provided by the manufacturer, distributor, wholesaler or traders). Market share analysis, assigned to each of the segments and regions are achieved through product utilization rate and average selling price.
Major manufacturers & their revenues, percentage splits, market shares, growth rates and breakdowns of the product markets are determined through secondary sources and verified through the primary sources.
All possible factors that influence the markets included in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. The market size for top-level markets and sub-segments is normalized, and the effect of inflation, economic downturns, and regulatory & policy changes or others factors are accounted for in the market forecast. This data is combined and added with detailed inputs and analysis from Vision Research Reports and presented in this report.
Market Breakdown and Data Triangulation
After complete market engineering with calculations for market statistics; market size estimations; market forecasting; market breakdown; and data triangulation. Extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub-segments listed in this report.
Secondary Sources occupies approximately 25% of data sources, such as press releases, annual reports, Non-Profit organizations, industry associations, governmental agencies and customs data, and so on. This research study includes secondary sources; directories; databases such as Bloomberg Business, Wind Info, Hoovers, Factiva (Dow Jones & Company), TRADING ECONOMICS, and avention; Investing News Network; statista; Federal Reserve Economic Data; annual reports; investor presentations; and SEC filings of companies.
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include product manufacturers (and their competitors), opinion leaders, industry experts, research institutions, distributors, dealer and traders, as well as the raw materials suppliers and producers, etc.
The primary sources from the demand side include industry experts such as business leaders, marketing and sales directors, technology and innovation directors, supply chain executive, end users (product buyers), and related key executives from various key companies and organizations operating in the global market.
The study objectives of this report are:
To strategically profile the key players and comprehensively analyze their growth strategies.
Dystrophic Epidermolysis Bullosa Treatment Market (By Treatment Type: Antibiotics, Corticosteroids, Opioid Analgesics, Anticonvulsant, Others; By Disease Type: DDEB and RDEB; By Distribution Channel) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2021-2030Read more...
Bromelain Market (By Application: Food & Beverages, Healthcare & Pharmaceuticals, Cosmetics, and Other Industries; By Source: Stem and Fruit) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2021-2030Read more...
Chronic Idiopathic Constipation Treatment Market (By Drug Class: Serotonin-4 [5-Ht4] Receptor Agonist, Guanylate Cyclase-C Agonist, Laxatives, Stimulants, Others; By Route of Administration: Oral and Rectal; By Distribution Channel) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2021-2030Read more...
Hemoglobin Feed Market (By Source: Bovine, Swine, Poultry, Shark, Synthetic, Others; By Application: Industrial and Commercial) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2021-2030Read more...
Respiratory Virus Infection Drugs Market (By Drug Type: Cough Suppressants, Antibiotics, Non-Steroidal Anti-Inflammatory Drugs [NSAIDS], Nasal Decongestants, and Others; By Infection Type, By Route of Administration, By Mode of Purchase, By Distribution Channel) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2021-2030Read more...